Stem Cell Clinic

Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy fo | DDDT – Dove Medical Press

Liming Wang,1,* Shigao Huang,2,* Shimei Li,1 Ming Li,1 Jun Shi,1 Wen Bai,1 Qianyun Wang,1 Libo Zheng,3 Yongjun Liu3

1Cell Therapy Center, 986 Hospital of Peoples Liberation Army Air Force, Xian, Shaanxi, Peoples Republic of China; 2Cancer Center, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macao SAR, Peoples Republic of China; 3Stem Cell Biology and Regenerative Medicine Institution, Yi-Chuang Institute of Bio-Industry, Beijing, Peoples Republic of China

*These authors contributed equally to this work

Correspondence: Shigao HuangCancer Center, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Room 3013, Building N-22, Taipa, Macau, Peoples Republic of ChinaEmail huangshigao2010@aliyun.comYongjun LiuStem Cell Biology and Regenerative Medicine Institution, Yi-Chuang Institute of Bio-Industry, No. 35, Jinghai 3 Road Economic-Technological Development Area, Beijing, Peoples Republic of ChinaEmail andyliuliu2001@aliyun.com

Background: The traditional anti-inflammation disease-modifying anti-rheumatic drugs (DMARDs) have limited therapeutic effects in rheumatoid arthritis (RA) patients. We previously reported the safety and efficacy of umbilical cord mesenchymal stem cell (UC-MSC) treatment in RA patients that were observed for up to 8 months after UC-MSC infusion. The aim of this study is to assess the long-term efficacy and safety of UC-MSC along with DMARDs for the treatment of RA.Methods: 64 RA patients aged 1864 years were recruited in the study. During the treatment, patients were treated with 40 mL UC-MSC suspension product (2 107 cells/20 mL) via intravenous injection immediately after the infusion of 100 mL saline. The serological markers tests were used to assess safety and the 28-joint disease activity score (DAS28) and the Health Assessment Questionnaire (HAQ) to assess efficacy.Results: 1 year and 3 years after UC-MSC cells treatment, the blood routine, liver and kidney function and immunoglobulin examination showed no abnormalities, which were all in the normal range. The ESR, CRP, RF of 1 year and 3 years after treatment and anti-CCP of 3 years after treatment were detected to be lower than that of pretreatment, which showed significant change (P < 0.05). Health index (HAQ) and joint function index (DAS28) decreased 1 year and 3 years after treatment than before treatment (P < 0.05).Conclusion: UC-MSC cells plus DMARDs therapy can be a safe, effective and feasible therapeutic option for RA patients.

Keywords: rheumatoid arthritis, umbilical cord mesenchymal stem cell, cell therapy

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read more:
Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy fo | DDDT - Dove Medical Press

Stem Cell Therapy is a Must Try Method for Permanent Relief from Pain, Says Integrated Medical Center of Corona – Press Release – Digital Journal

Corona, CA - December 19, 2019 - Chronic pain can be debilitating, and it drastically reduces the quality of life. Until recently, patients had to go through the dread of operations, surgeries, pain killers and downtime, but no longer. At the Integrated Medical Center of Corona, stem cell therapy today allows doing away with the very source of pain in an office setting, without having to go under the knife.

It could be called soup therapy for muscles, joints and tendons. The soup here comprises a powerful and healing concoction of stem cells, ozone, and plasma rich platelets, which is directly injected into the affected region. These ingredients replace the pain causing cells and naturally replace them with healthy, regenerated, identical cells.

Many of the patients at the Integrated Medical Center of Corona vouch for the efficacy and ease with which they got rid of chronic painful conditions in the neck, joints, hips or shoulders. With no risky surgery or harmful drugs involved, a non-invasive, quick procedure in an office setting is all it took to bring back the old lifestyle!

For years, patients have been forced to fly to other countries around the world to experience the healing miracle of Regenerative Medicine. Now it is available right here in your local community, with complete professionalism. We treat our patients as family. It is that simple, says Dr. Anthony Pirritano, owner of IMCC.

With regenerative therapy, chronic pain can be quickly and completely eliminated. A single visit brings about great relief. There is no downtime in bed or use of crutches or slings. Stem cell therapy allows patients to live a completely pain free life.

The Clinic is led by Dr. Anthony Pirritano, who has been practicing for over 20 years helping patients live a pain-free life with proven cellular therapies. With the most advanced techniques and high levels of service, the Clinic offers a serene and relaxing ambience to receive the most advanced pain relieving therapies.

Integrated Medical Center of Corona offers everyone a free consultation on how stem cell and regenerative therapy can help get rid of painful conditions.

About

Integrated Medical is a full-service, comprehensive wellness center dedicated to specialized, non-invasive, and rehabilitative medicine. Passionate about excellence in patient care, Integrated Medical Center provides traditional and holistic treatment for a wide variety of ailments, including most musculoskeletal injuries (whiplash, neck, low back pain, headaches, knee pain, pain/numbness in the arms or legs, etc.), weight gain, hormonal issues (low testosterone), pain management, and many other conditions.

For more information, please visit: http://www.integratedmedicalcenterofcorona.com

Media ContactCompany Name: Integrated Medical Center of CoronaContact Person: Jason Kimes, Marketing ManagerEmail: Send EmailPhone: (800) 595-2447Address:2250 S. Main Street, Suite # 203 City: CoronaState: CACountry: United StatesWebsite: https://www.integratedmedicalcenterofcorona.com/

See original here:
Stem Cell Therapy is a Must Try Method for Permanent Relief from Pain, Says Integrated Medical Center of Corona - Press Release - Digital Journal

Hackensack Meridian Health and Georgetown Lombardi Comprehensive Cancer Center Become Associate Members of the New York Genome Center – BioSpace

NEW YORK, Dec. 19, 2019 /PRNewswire/ --The New York Genome Center (NYGC) announced today that Hackensack Meridian Health and the Georgetown Lombardi Comprehensive Cancer Center have become the two newest institutional associate members of the NYGC.

Hackensack Meridian Health is New Jersey's largest health care network. Its Center for Discovery and Innovation (CDI) and John Theurer Cancer Center at Hackensack University Medical Center, a member of the Georgetown Lombardi consortium, are key components of the network's strategy to develop and employ the latest genomic medicine for patients. Georgetown Lombardi Comprehensive Cancer Center is Washington, D.C.'s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center and NCI-approved consortium.

"We are excited to have these leading institutions with distinguished physician-scientists and researchers join the New York Genome Center community," said Tom Maniatis, PhD, Evnin Family Scientific Director and Chief Executive Officer, NYGC. "We look forward to working with their teams to further our collaborative efforts to accelerate genomics research."

"The Center for Discovery and Innovation is a key element of our mission to transform health care and lead toward the future," said Robert C. Garrett, FACHE, Chief Executive Officer, Hackensack Meridian Health. "The John Theurer Cancer Center continues to provide the most advanced care currently available. Through our new partnerships at the New York Genome Center, patients in New Jersey and beyond will benefit from the latest technologies for personalized medicine."

"The New York Genome Center is a unique and critical nexus for research collaboration in the genomics community, and the Georgetown Lombardi Comprehensive Cancer Center consortium is pleased to join NYGC's member institutions to partner in cancer genomics research," said Louis M. Weiner, MD, Director, Georgetown Lombardi Comprehensive Cancer Center and the MedStar Georgetown Cancer Institute.

The new members are joining the NYGC through two separate partnerships with distinct collaborative research objectives. The first partnership, to be led by Hackensack Meridian Health's CDI, is focused on exploring the genetics underlying the risk factors for behavioral disorders and identifying genetic markers that help physicians predict and manage these disorders more effectively. The second partnership is focused on cancer genomics and led by Georgetown Lombardi Comprehensive Cancer Center, which includes investigators from Georgetown University Medical Center, along with the Hackensack Meridian Health's John Theurer Cancer Center and CDI. This partnership will seek to use advanced genetic analyses to better understand risk factors for emergence of certain aggressive cancers, such as pediatric brain tumors; why certain cancers fail to respond to immunotherapy; and identify genetic markers or cellular factors that can improve patient outcomes.

"This is a leap forward for the CDI and its mission to translate scientific innovation from the laboratory to treatments for patients," said David S. Perlin, PhD, Chief Scientific Officer and Senior Vice President of the CDI. "Our world-class scientists will benefit from connecting and collaborating with colleagues at leading New York-region institutions."

Given their areas of research focus, Hackensack Meridian Healthand Georgetown Lombardi Comprehensive Cancer Center will be participants in the Genome Center Cancer Group (GCCG), NYGC's founding scientific working group, which is composed of clinicians and cancer researchers from NYGC's member institutions. With the addition of these new members, the GCCG now includes seven NCI-designated Comprehensive Cancer Centers. The GCCG is led by Nobel Laureate Harold Varmus, MD, Senior Associate Core Member, NYGC, and Lewis Thomas University Professor of Medicine, Weill Cornell Medicine, and Charles Sawyers, MD, Chair, Human Oncology and Pathogenesis Program, Marie-Jose and Henry R. Kravis Chair, Memorial Sloan Kettering Cancer Center, and Affiliate Member, NYGC. The GCCG recently launched Polyethnic-1000, a project to study cancer in ethnically diverse, underserved patient populations, and is also spearheading the multi-institutional Very Rare Cancer Consortium, a research cohort focused on understanding the genetic causes for rare, understudied cancers. In addition, the NYGC is utilizing the application of novel statistical approaches and population-level analyses to major cohorts in cancer genomics.

Researchers from Hackensack Meridian Health's CDI also are expected to engage in NYGC's Neuropsychiatric Disease Scientific Working Group. It is led by Dr. Maniatis; Michael Zody, PhD, Scientific Director, Computational Biology; and Thomas Lehner, PhD, MPH, formerly of the National Institute of Mental Health of the National Institutes of Health, who arrives to the NYGC in January in the new position of Scientific Director of Neuropsychiatric Disease Genomics. Reporting to Dr. Maniatis, Dr. Lehner will lead the expansion of the NYGC's innovative, large-scale whole genome autism research into other neuropsychiatric disease areas, including schizophrenia and bipolar disorder.

Georgetown Lombardi Comprehensive Cancer Center and Hackensack Meridian Health join NYGC's institutional associate members, which include American Museum of Natural History, Hospital for Special Surgery, The New York Stem Cell Foundation, Princeton University, and Roswell Park Cancer Institute, and its 12 institutional founding members: Cold Spring Harbor Laboratory, Columbia University, Albert Einstein College of Medicine, The Jackson Laboratory, Memorial Sloan Kettering Cancer Center, Icahn School of Medicine at Mount Sinai, New York-Presbyterian Hospital, New York University, Northwell Health, The Rockefeller University, Stony Brook University, and Weill Cornell Medicine.

About the New York Genome Center The New York Genome Center (NYGC) is an independent, nonprofit academic research institution focused on furthering genomic research that leads to scientific advances and new insights and therapies for patients with neurodegenerative disease, neuropsychiatric disease, and cancer. Leveraging our strengths in whole genome sequencing, genomic analysis, and development of new genomic tools, the NYGC serves as a nexus for collaboration in disease-focused genomic research for the New York medical and academic communities and beyond.

NYGC harnesses the expertise and builds on the combined strengths of our faculty, staff scientists, member institutions, scientific working groups, affiliate members, and industry partners to advance genomic discovery. Central to our scientific mission is an outstanding faculty who lead independent research labs based at the NYGC, and hold joint tenure-track appointments with one of our member institutions.

Institutional founding members of the NYGC are: Cold Spring Harbor Laboratory, Columbia University, Albert Einstein College of Medicine, The Jackson Laboratory, Memorial Sloan Kettering Cancer Center, Icahn School of Medicine at Mount Sinai, New York-Presbyterian Hospital, New York University, Northwell Health, The Rockefeller University, Stony Brook University, and Weill Cornell Medicine. Institutional associate members are: American Museum of Natural History, Georgetown Lombardi Comprehensive Cancer Center, Hackensack Meridian Health, Hospital for Special Surgery, The New York Stem Cell Foundation, Princeton University, and Roswell Park Cancer Institute.

For more information on the NYGC, please visit:http://www.nygenome.org.

Media Contact:Karen Zipern, Director, Communications, NYGCkzipern@nygenome.orgo: 646-977-7065c: 917-415-8134

View original content:http://www.prnewswire.com/news-releases/hackensack-meridian-health-and-georgetown-lombardi-comprehensive-cancer-center-become-associate-members-of-the-new-york-genome-center-300977742.html

SOURCE New York Genome Center

See the original post here:
Hackensack Meridian Health and Georgetown Lombardi Comprehensive Cancer Center Become Associate Members of the New York Genome Center - BioSpace

Orthopaedic Surgeon, Dr. Jeffrey Carlson, first in Central and Eastern Virginia to implant the M6-C Artificial Cervical Disc – OrthoSpineNews

NEWPORT NEWS, Va.,Dec. 18, 2019/PRNewswire/ Orthopaedic and Spine Center announced Dr.Jeffrey Carlson, Orthopaedic Spine Surgeon, became the first surgeon in Central andEastern Virginiaarea to implant the M6-Cartificial cervical disc. The outpatient surgery was performed on a 53 year old female at Bon Secours/Mercy Health Mary Immaculate Hospital inNewport News, VirginiaonNovember 20, 2019.

The patient reported symptoms of severe neck pain which radiated to both shoulders after a motor vehicle accident. After she failed to respond to conservative treatment, an MRI was ordered revealing severe spinal stenosis and spinal cord abutment at level C3-4 caused by a herniated disc. In consultation with Dr. Carlson, the patient made the decision to have cervical disc arthroplasty, using the Orthofix M6-C artificial cervical disc.

Ive been waiting for the right patient with the appropriate diagnosis to employ the M6-C disc, said Carlson. The technology used in this procedure facilitates a speedy recovery with minimal limitations and a great outcome, so that my patient can get back to her active life. She just had her two week post-surgical follow-up appointment her recovery is going very well and she feels much relief from the severe pain she once experienced.

The M6-C disc received U.S. Food and Drug Approval in February 2019.It was designed to closely mimic the anatomic structure of a natural disc as well as provide an effective alternative to a spinal fusion. By allowing the spine to move naturally, the M6-C artificial disc potentially minimizes stress to adjacent discs and other vertebral structures.

AboutJeffrey R. Carlson, M.D.Dr.Jeffrey Carlsonhas been a part of Orthopaedic & Spine Center since 1999 and serves as the President and Managing Partner. He is a board-certified, fellowship-trained orthopaedic surgeon who focuses on the treatment of injuries and disorders of the spine.

About Orthopaedic & Spine CenterOrthopaedic & Spine Center (OSC) is staffed by outstanding medical professionals who strive to provide the very best orthopaedic and interventional pain management care available anywhere. Our Center includes a comfortable, state-of-the-art medical facility, pleasant and well-trained personnel, physicians trained in the most advanced orthopaedic treatments, interventional pain management procedures, regenerative medicine, using stem cell and platelet therapies and a dedication to old-fashioned patient care.

SOURCE Orthopaedic & Spine Center

osc-ortho.com

Read this article:
Orthopaedic Surgeon, Dr. Jeffrey Carlson, first in Central and Eastern Virginia to implant the M6-C Artificial Cervical Disc - OrthoSpineNews

Experts and Attitude Help Grandfather Face Primary Central Nervous System Lymphoma – Dana-Farber Cancer Institute

Steve Kelley is the quintessential glass half-full guy. Still, he realizes his reaction to learning he had an extremely rare cancer known as central nervous system (CNS) lymphoma may seem unusual.

Afew weeks after his June 2018 diagnosis, Kelley, then 64, gathered his familyand friends together. He didnt want to focus negatively on the uncertainoutcome or his upcoming treatment at Dana-Farber/Brigham and Womens CancerCenter (DF/BWCC).

Hejust wanted to celebrate the present.

Ive always seen myself as someone who deals with whatever life puts in front of me, says Kelley of the pre-treatment party he organized at a bowling alley near his home in Sharon, Mass. I wanted everybody to know I felt the same way now, even with cancer. I was celebrating the challenge ahead.

Sincethen, through intensive chemotherapy, followed by an autologous stem celltransplant in November 2018, and then several months re-strengthening hisimmune system, the father and grandfather of four has kept up this positivity.

Whileits true he lost his hair, fingernails, and dealt with other serious sideeffects during treatment, Kelley explains, things have greatly improved sincethen. Forced to go without his favorite activities of swimming and mountain bikingfor a while, he is now feeling strong enough to think about triathlons. Heseven handling snow plowing and other duties associated with the real estatemanagement and roofing businesses he founded at age 19, and still leads today withthe help of sons Phil and Dave.

Andif he must be among those living with primary CNS lymphoma, Kelley says, he couldnthave picked a better time or place.

The Central Nervous System Lymphoma Center, established at DF/BWCC in December 2017, was the first facility in the world dedicated to providing comprehensive care and research for patients with this rare cancer. The center offers advanced treatment options including surgical biopsy, chemotherapy, radiation therapy, immunotherapy, and targeted therapy, as well as placement for qualified patients on clinical trials.

Itell you, Im one lucky son of a gun, says Kelley.

Itis Kelleys upbeat attitude, he believes, that led him to initially miss the warningsigns of his CNS lymphoma. Two areas impacted by the cancer are eyesight and orientation;although he had been having trouble with both for several months, he says helearned to subconsciously compensate.

Asstrange as it sounds, I would tilt my head left or right to see, says Kelley.Things didnt get really bad until one day when I was driving six miles to myhouse on a route I had known for years. There wasnt a lot of traffic, but Ikept seeing lines across my eyes, and was so disoriented it took me three hoursto get home. When I told my wife, she insisted we go to the nearest emergencyroom.

There an MRI revealed a mass in Kelleys head, and he was immediately sent to DF/BWCC for more tests. He then had what he calls another stroke of good fortune, in the form of oncologist Lakshmi Nayak, MD, director of the Central Nervous System Lymphoma Center. Right away, Nayak and physician assistant Alexandra Torres, PA-C, put Kelley at ease with their knowledge and warmth.

Dr. Nayak analyzed my condition and synthesized a treatment plan that brought me back from the kind of a cliff that I was holding onto, Kelley says. She was terrific.

Similarly,Nayak says, Kelleys approach to that plan was helpful.

Hewas certainly a perfect candidate for undergoing an autologous transplantbecause of his age and fitness, says Nayak, but importantly, his attitudethroughout the arduous process was amazing.

Kelley, who meets regularly with Nayak and her team for checkups, has not yet had a cancer recurrence. Recently he marked a year since his stem cell transplant with another celebration Thanksgiving with his family and in March he plans to meet with a specialist at DF/BWCC to work on improving the cognitive skills impacted by his diagnosis.

Meanwhile, with the ongoing support of his incredible wife, family, and close friends, Kelley is keeping his spirits up and forging ahead. In addition to running his company, he is enjoying a 20-year secondary career as a Cambridge College professor. Among the courses he teaches are leadership, conflict management, and effective listening, all of which he says have been indispensable guideposts in his recovery.

Its funny I was already working on writing a book about how people can help themselves through tough times, and now Im reworking it to include my cancer journey, Kelley says. One of the things I like to tell people is that maturity is the ability to make the best of any situation.

I hope to be proof of that.

Read this article:
Experts and Attitude Help Grandfather Face Primary Central Nervous System Lymphoma - Dana-Farber Cancer Institute